Claims
- 1-10. (Cancelled).
- 11. A method of milling a pharmaceutical product comprising:
(a) providing a dispersion containing the product to be milled and attrition milling media, wherein the attrition milling media has a mean particle size of less than about 1000 microns; (b) inserting the dispersion into a vessel; (c) providing an agitator and a coupling that closes the vessel, the coupling having an opening through which a portion of the agitator extends, the agitator comprising a rotor and a shaft extending therefrom, wherein the rotor is dimensioned so that an outer periphery is no greater than 3 mm away from an inner surface of the wall of the vessel; (d) inserting the agitator into the vessel and sealingly closing the coupling, wherein the vessel is filled so that the dispersion eliminates substantially all of the air in the vessel when the agitator is fully inserted into the vessel; and (e) rotating the agitator for a predetermined period, wherein the resulting milled pharmaceutical product has a submicron mean particle size.
- 12. The method of claim 11, wherein the pharmaceutical product is milled in the presence of at least one surface modifier.
- 13. The method of claim 12, wherein the at least one surface modifier is selected from the group consisting of gelatin, casein, lecithin, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glyceryl monostearate, cetostearl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyethylene glycols, polyoxyethylene stearates, colloidol silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethycellulose phthalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol, polyvinylpyrrolidone, block copolymers of ethylene oxide and propylene oxide, a tetrafunctional block copolymer derived from sequential addition of ethylene oxide and propylene oxide to ethylenediamine, dextran, a dioctyl ester of sodium sulfosuccinic acid, a sodium lauryl sulfate, and an alkyl aryl polyether sulfonate.
- 14. The method of claim 12, wherein the ratio of the distance between the outer periphery of the rotor and the inner surface of the wall to the attrition milling media nominal size is about 6 to about 1.
- 15. The method of claim 12, wherein the attrition media has a mean particle size selected from the group consisting of: (a) less than about 500 microns; (b) less than about 300 microns; (c) less than about 250 microns; (d) less than about 200 microns; (e) less than about 100 microns; (f) less than about 75 microns; (g) less than about 50 microns, (h) less than about 25 microns; (i) less than about 5 microns; and (j) a mixture thereof.
- 16. The method of claim 12, wherein the attrition media is selected from the group consisting of polymeric, zirconium oxide, zirconium silicate, glass, stainless steel, titania, alumina, and 95% ZrO stabilized with yttrium.
- 17. The method of claim 12, wherein the working volume of the vessel is about 12 mL to about 33 mL.
- 18. The method of claim 12, wherein the volume of the dispersion is about 5 ml to about 23 mL.
- 19. The method of claim 12, wherein the volume of the dispersion is less than about 10 mL.
- 20. The method of claim 12, wherein the method further comprises maintaining substantially uniform shear between the rotor and the and the cylindrical vessel.
- 21. The method of claim 12, wherein at the completion of the rotation period, the pharmaceutical product has an average particle size selected from the group consisting of less than about 500 nm, less than about 400 nm, less than about 300 nm, and less than about 100 nm.
- 22. The method of claim 21, wherein at least 90% of the milled pharmaceutical product particles have a size less than that selected from the group consisting of less than about 500 nm, less than about 400 nm, less than about 300 nm, and less than about 100 nm.
- 23. The method of claim 21, wherein at least 95% of the milled pharmaceutical product particles have a size less than that selected from the group consisting of less than about 500 nm, less than about 400 nm, less than about 300 nm, and less than about 100 nm.
- 24. The method of claim 21, wherein at least 99% of the milled pharmaceutical product particles have a size less than that selected from the group consisting of less than about 500 nm, less than about 400 nm, less than about 300 nm, and less than about 100 nm.
- 25. The method of claim 12, wherein the dispersion is recirculated through the vessel during rotation of the agitator.
- 26. The method of claim 12, wherein the pharmaceutical product is a heat sensitive product.
- 27. The method of claim 12, wherein the pharmaceutical product is selected from the group consisting of analgesics, anti-inflammatory agents, anthelmintics, anti-arrhythmic agents, antibiotics, anticoagulants, antidepressants, antidiabetic agents, antiepileptics, antihistamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants, antithyroid agents, antiviral agents, anxiolytic sedatives, astringents, beta-adrenoceptor blocking agents, blood products, blood substitutes, cardiac inotropic agents, contrast media, corticosteroids, cough suppressants, diagnostic agents, diagnostic imaging agents, diuretics, dopaminergics, haemostatics, immunological agents, lipid regulating agents, muscle relaxants, parasympathomimetics, parathyroid calcitonin, parathyroid biphosphonates, prostaglandins, radio-pharmaceuticals, sex hormones, anti-allergic agents, stimulants, anoretics, sympathomimetics, thyroid agents, vasodilators, and xanthines.
- 28. The method of claim 12, wherein the product is an NSAID.
- 29. The method of claim 28, wherein the NSAID is selected from the group consisting of nabumetone, tiaramide, proquazone, bufexamac, flumizole, epirazole, tinoridine, timegadine, dapsone, aspirin, diclofenac, alclofenac, fenclofenac, etodolac, indomethacin, sulindac, tolmetin, fentiazac, tilomisole, carprofen, fenbufen, flurbiprofen, ketoprofen, oxaprozin, suprofen, tiaprofenic acid, ibuprofen, naproxen, fenoprofen, indoprofen, pirprofen, flufenamic, mefenamic, meclofenamic, niflumic, oxyphenbutazone, phenylbutazone, apazone, feprazone, piroxicam, sudoxicam, isoxicam, and tenoxicam.
- 30. The method of claim 12, wherein the product is an anticancer agent.
- 31. The method of claim 30, wherein the anticancer agent is selected from the group consisting of alkylating agents, antimetabolites, natural products, hormones, and antagonists.
- 32. The method of claim 31, wherein the anticancer agent is selected from the group consisting of: (1) alkylating agents having the bis-(2-chloroethyl)-amine group; (2) alkylating agents having a substituted aziridine group; (3) alkylating agents of the alkyl sulfonate type; (4) alkylating N-alkyl-N-nitrosourea derivatives; (5) alkylating agents of the mitobronitole type; (6) alkylating agents of the dacarbazine type; and (7) alkylating agents of the procarbazine type.
- 33. The method of claim 32, wherein the anticancer agent is selected from the group consisting of chlormethine, chlorambucile, melphalan, uramustine, mannomustine, extramustinephoshate, mechlore-thaminoxide, cyclophosphamide, ifosfamide, trifosfamide, tretamine, thiotepa, triaziquone, mitomycine, busulfan, piposulfan, piposulfam, carmustine, lomustine, semustine, streptozotocine.
- 34. The method of claim 31, wherein the anticancer agent is selected from the group consisting of: (1) folic acid analogs; (2) pyrimidine analogs; and (3) purine derivatives.
- 35. The method of claim 34, wherein the anticancer agent is selected from the group consisting of methotrexate, fluorouracil, floxuridine, tegafur, cytarabine, idoxuridine, flucytosine, mercaptopurine, thioguanine, azathioprine, tiamiprine, vidarabine, pentostatin, and puromycine.
- 36. The method of claim 31, wherein the anticancer agent is selected from the group consisting of vinca alkaloids, epipodophylotoxins, antibiotics, enzymes, biological response modifiers, camptothecin, taxol, and retinoids.
- 37. The method of claim 36, wherein the anticancer agent is selected from the group consisting of vinblastine, vincristine, etoposide, teniposide, adriamycine, daunomycine, doctinomycin, daunorubicin, doxorubicin, mithramycin, bleomycin, mitomycin, L-asparaginase, alpha-interferon and retinoic acid.
- 38. The method of claim 31, wherein the anticancer agent is selected from the group consisting of adrenocorticosteroids, progestins, estrogens, antiestrogens, androgens, antiandrogens, and gonadotropin-releasing hormone analogs.
- 39. The method of claim 38, wherein the anticancer agent is selected from the group consisting of prednisone, hydroxyprogesterone caproate, medroxyprogesterone acetate, megestrol acetate, diethylstilbestrol, ethinyl estradiol, tamoxifen, testosterone propionate, fluoxymesterone, flutamide, and leuprolide.
- 40. The method of claim 31, wherein the anticancer agent is selected from the group consisting of radiosensitizers, platinum coordination complexes, anthracenediones, substituted ureas, adrenocortical suppressants, and an immunosuppressive drug.
- 41. A method of milling a human or animal ingestable product comprising:
(a) providing a dispersion containing the product to be milled and attrition milling media, wherein the attrition milling media has a mean particle size of less than about 1000 microns; (b) inserting the dispersion into a vessel; (c) providing an agitator and a coupling that closes the vessel, the coupling having an opening through which a portion of the agitator extends, the agitator comprising a rotor and a shaft extending therefrom, wherein the rotor is dimensioned so that an outer periphery is no greater than 3 mm away from an inner surface of the vessel wall; (d) inserting the agitator into the vessel and sealingly closing the coupling, wherein the vessel is filled so that the dispersion eliminates substantially all of the air in the vessel when the agitator is fully inserted into the vessel; and (e) rotating the agitator for a predetermined period, wherein the resulting human or animal ingestable product has a submicron mean particle size.
- 42. The method of claim 41, wherein the human or animal ingestable product is milled in the presence of at least one surface modifier.
- 43. The method of claim 42, wherein the at least one surface modifier is selected from the group consisting of gelatin, casein, lecithin, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glyceryl monostearate, cetostearl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyethylene glycols, polyoxyethylene stearates, colloidol silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethycellulose phthalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol, polyvinylpyrrolidone, block copolymers of ethylene oxide and propylene oxide, a tetrafunctional block copolymer derived from sequential addition of ethylene oxide and propylene oxide to ethylenediamine, dextran, a dioctyl ester of sodium sulfosuccinic acid, a sodium lauryl sulfate, and an alkyl aryl polyether sulfonate.
- 44. The method of claim 42, wherein the ratio of the distance between the outer periphery of the rotor and the inner surface of the wall to the attrition milling media nominal size is about 6 to about 1.
- 45. The method of claim 42, wherein the attrition media has a mean particle size selected from the group consisting of: (a) less than about 500 microns; (b) less than about 300 microns; (c) less than about 250 microns; (d) less than about 200 microns; (e) less than about 100 microns; (f) less than about 75 microns; (g) less than about 50 microns, (h) less than about 25 microns; (i) less than about 5 microns; and (j) a mixture thereof.
- 46. The method of claim 42, wherein the attrition media is selected from the group consisting of polymeric, zirconium oxide, zirconium silicate, glass, stainless steel, titania, alumina, and 95% ZrO stabilized with yttrium.
- 47. The method of claim 42, wherein the working volume of the vessel is about 12 mL to about 33 mL.
- 48. The method of claim 42, wherein the volume of the dispersion is about 5 ml to about 23 mL.
- 49. The method of claim 42, wherein the volume of the dispersion is less than about 10 mL.
- 50. The method of claim 42, wherein the method further comprises maintaining substantially uniform shear between the rotor and the and the vessel.
- 51. The method of claim 42, wherein at the completion of the rotation period, the human or animal ingestable product has an average particle size selected from the group consisting of less than about 500 nm, less than about 400 nm, less than about 300 nm, and less than about 100 nm.
- 52. The method of claim 51, wherein at least 90% of the milled human or animal ingestable product particles have a size less than that selected from the group consisting of less than about 500 nm, less than about 400 nm, less than about 300 nm, and less than about 100 nm.
- 53. The method of claim 51, wherein at least 95% of the milled human or animal ingestable product particles have a size less than that selected from the group consisting of less than about 500 nm, less than about 400 nm, less than about 300 nm, and less than about 100 nm.
- 54. The method of claim 51, wherein at least 99% of the milled human or animal ingestable product particles have a size less than that selected from the group consisting of less than about 500 nm, less than about 400 nm, less than about 300 nm, and less than about 100 nm.
- 55. The method of claim 42, wherein the dispersion is recirculated through the vessel during rotation of the agitator.
- 56. A method of milling a cosmetic product comprising:
(a) providing a dispersion containing the product to be milled and attrition milling media, wherein the attrition milling media has a mean particle size of less than about 1000 microns (b) inserting the dispersion into a vessel; (c) providing an agitator and a coupling that closes the vessel, the coupling having an opening through which a portion of the agitator extends, the agitator comprising a rotor and a shaft extending therefrom, wherein the rotor is dimensioned so that an outer periphery is no greater than 3 mm away from an inner surface of the vessel wall; (d) inserting the agitator into the vessel and sealingly closing the coupling, wherein the vessel is filled so that the dispersion eliminates substantially all of the air in the vessel when the agitator is fully inserted into the vessel; and (e) rotating the agitator for a predetermined period, wherein the resulting cosmetic product has a submicron mean particle size.
- 57. The method of claim 56, wherein the cosmetic product is milled in the presence of at least one surface modifier.
- 58. The method of claim 57, wherein the at least one surface modifier is selected from the group consisting of gelatin, casein, lecithin, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glyceryl monostearate, cetostearl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyethylene glycols, polyoxyethylene stearates, colloidol silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethycellulose phthalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol, polyvinylpyrrolidone, block copolymers of ethylene oxide and propylene oxide, a tetrafunctional block copolymer derived from sequential addition of ethylene oxide and propylene oxide to ethylenediamine, dextran, a dioctyl ester of sodium sulfosuccinic acid, a sodium lauryl sulfate, and an alkyl aryl polyether sulfonate.
- 59. The method of claim 57, wherein the ratio of the distance between the outer periphery of the rotor and the inner surface of the wall to the attrition milling media nominal size is about 6 to about 1.
- 60. The method of claim 57, wherein the attrition media has a mean particle size selected from the group consisting of: (a) less than about 500 microns; (b) less than about 300 microns; (c) less than about 250 microns; (d) less than about 200 microns; (e) less than about 100 microns; (f) less than about 75 microns; (g) less than about 50 microns, (h) less than about 25 microns; (i) less than about 5 microns; and (j) a mixture thereof.
- 61. The method of claim 57, wherein the attrition media is selected from the group consisting of polymeric, zirconium oxide, zirconium silicate, glass, stainless steel, titania, alumina, and 95% ZrO stabilized with yttrium.
- 62. The method of claim 57, wherein the working volume of the vessel is about 12 mL to about 33 mL.
- 63. The method of claim 57, wherein the volume of the dispersion is about 5 ml to about 23 mL.
- 64. The method of claim 57, wherein the volume of the dispersion is less than about 10 mL.
- 65. The method of claim 57, wherein the method further comprises maintaining substantially uniform shear between the rotor and the and the vessel.
- 66. The method of claim 57, wherein at the completion of the rotation period, the cosmetic product has an average particle size selected from the group consisting of less than about 500 nm, less than about 400 nm, less than about 300 nm, and less than about 100 nm.
- 67. The method of claim 66, wherein at least 90% of the milled cosmetic product particles have a size less than that selected from the group consisting of less than about 500 nm, less than about 400 nm, less than about 300 nm, and less than about 100 nm.
- 68. The method of claim 66, wherein at least 95% of the milled cosmetic product particles have a size less than that selected from the group consisting of less than about 500 nm, less than about 400 nm, less than about 300 nm, and less than about 100 nm.
- 69. The method of claim 66, wherein at least 99% of the milled cosmetic product particles have a size less than that selected from the group consisting of less than about 500 nm, less than about 400 nm, less than about 300 nm, and less than about 100 nm.
- 70. The method of claim 57, wherein the dispersion is recirculated through the vessel during rotation of the agitator.
RELATED APPLICATIONS
[0001] This is a divisional application of Co-Pending application Ser. No. 09/583,893, filed May 31, 2000, entitled SMALL-SCALE MILL AND METHOD THEREOF, which is based on Provisional application No. 60/137,142, filed Jun. 1, 1999 and all of whose entire disclosures are incorporated by reference herein.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60137142 |
Jun 1999 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09583893 |
May 2000 |
US |
Child |
10037566 |
Oct 2001 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
10037566 |
Oct 2001 |
US |
Child |
10833045 |
Apr 2004 |
US |